Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.61 |
| ▸ | BRAF | P15056 | 4/20 | 0.57 |
| ▸ | CDK8 | P49336 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 5/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | WRN | Q14191 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104548 | 0.88 | CA7 (0.63) | NAMPTBRAFCDK8KDRMAPK14 | |
| SCHEMBL16990727 | 0.88 | RAF1 (0.60) | NAMPTBRAFKDRMAPK14TNNI3K | |
| SCHEMBL939171 | 0.88 | CDK8 (0.70) | BRAFCDK8KDRBLMWRN | |
| SCHEMBL15574842 | 0.84 | NAMPT (0.79) | NAMPTBRAFKDRMAPK14TNNI3K | |
| SCHEMBL16990586 | 0.82 | NAMPT (0.64) | NAMPTBRAFKDRMAPK14TNNI3K | |
| SCHEMBL15573250 | 0.82 | NAMPT (0.67) | NAMPTMAPK14 | |
| SCHEMBL15574787 | 0.82 | KDR (0.76) | NAMPTBRAFCDK8KDRMAPK14 | |
| SCHEMBL15573261 | 0.81 | NAMPT (0.76) | NAMPT | |
| SCHEMBL16990657 | 0.81 | HTT (0.60) | NAMPTMAPK14 | |
| SCHEMBL15574779 | 0.80 | TRPV1 (0.54) | NAMPTMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | claimed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | NAMPT 2021/4885BRAF 3224/4885CDK8 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.